Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798694 · ClinicalTrials.gov registry record · Phase 4
How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
A Phase 4 study of Glaucoma, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT00798694 is a Phase 4 study of Glaucoma that has completed, run by Wills Eye. The registered enrollment target is 58 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00798694, a Phase 4 study of Glaucoma, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.
Conditions Studied
Interventions
- DRUG Xalatan
- DRUG Travatan Z
Study Locations (1)
Pennsylvania
- Wills Eye Glaucoma Service - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00798694
The ClinicalTrials.gov registry entry for NCT00798694 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower). The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Xalatan is the first listed.
NCT00798694 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00798694 about?
NCT00798694 is a clinical study titled "How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?". To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.
What is the current status of trial NCT00798694?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2008-11. Estimated completion is 2011-02.
What conditions does trial NCT00798694 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00798694?
The interventions under investigation include: Xalatan (DRUG), Travatan Z (DRUG).
Who is sponsoring clinical trial NCT00798694?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00798694 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.